XRAY vs. NVST, APLS, ACHC, ENSG, IONS, INSP, ELAN, PCVX, RVMD, and JAZZ
Should you be buying DENTSPLY SIRONA stock or one of its competitors? The main competitors of DENTSPLY SIRONA include Envista (NVST), Apellis Pharmaceuticals (APLS), Acadia Healthcare (ACHC), The Ensign Group (ENSG), Ionis Pharmaceuticals (IONS), Inspire Medical Systems (INSP), Elanco Animal Health (ELAN), Vaxcyte (PCVX), Revolution Medicines (RVMD), and Jazz Pharmaceuticals (JAZZ). These companies are all part of the "medical" sector.
DENTSPLY SIRONA (NASDAQ:XRAY) and Envista (NYSE:NVST) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation, risk and community ranking.
In the previous week, DENTSPLY SIRONA and DENTSPLY SIRONA both had 10 articles in the media. DENTSPLY SIRONA's average media sentiment score of 0.86 beat Envista's score of 0.84 indicating that DENTSPLY SIRONA is being referred to more favorably in the media.
DENTSPLY SIRONA has a net margin of -3.33% compared to Envista's net margin of -3.90%. DENTSPLY SIRONA's return on equity of 11.14% beat Envista's return on equity.
Envista has lower revenue, but higher earnings than DENTSPLY SIRONA. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.
DENTSPLY SIRONA received 426 more outperform votes than Envista when rated by MarketBeat users. Likewise, 61.38% of users gave DENTSPLY SIRONA an outperform vote while only 40.30% of users gave Envista an outperform vote.
DENTSPLY SIRONA currently has a consensus price target of $39.50, suggesting a potential upside of 30.15%. Envista has a consensus price target of $27.90, suggesting a potential upside of 39.36%. Given Envista's higher possible upside, analysts plainly believe Envista is more favorable than DENTSPLY SIRONA.
DENTSPLY SIRONA has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Envista has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500.
95.7% of DENTSPLY SIRONA shares are held by institutional investors. 0.7% of DENTSPLY SIRONA shares are held by insiders. Comparatively, 1.3% of Envista shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
DENTSPLY SIRONA beats Envista on 11 of the 17 factors compared between the two stocks.
Get DENTSPLY SIRONA News Delivered to You Automatically
Sign up to receive the latest news and ratings for XRAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XRAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DENTSPLY SIRONA Competitors List
Related Companies and Tools
